Meng, Zhiqiang
7 papers on CoChatORCID 0000-0003-3593-6098
Most cited papers
- Verified
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 1,124
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 333
- Verified · note
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
Qin, S., Kudo, M., Meyer, T., Bai, Y., Guo, Y., Meng, Z., Satoh, T., Marino, D., Assenat, E., Li, S., et al. (2023) · JAMA Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 265
- Verified
Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma
Yu, S., Li, Y., Liao, Z., Wang, Z., Wang, Z., Li, Y., Qian, L., Zhao, J., Zong, H., Kang, B., et al. (2020) · Gut
Extracellular vesicles in diseasePancreatic and Hepatic Oncology Research
Cited by 241
- Verified
MicroRNA 23b Regulates Autophagy Associated With Radioresistance of Pancreatic Cancer Cells
Wang, P., Zhang, J., Zhang, L., Zhu, Z., Fan, J., Chen, L., Zhuang, L., Luo, J., Chen, H., Liu, L., et al. (2013) · Gastroenterology
MicroRNA in disease regulationAutophagy in Disease and Therapy
Cited by 234
- Verified
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010) · European Journal of Surgical Oncology (EJSO)
Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics
Cited by 128
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free